Literature DB >> 22720216

High expression of CD20+ lymphocytes in soft tissue sarcomas is a positive prognostic indicator.

Sveinung W Sorbye1, Thomas Kilvaer, Andrej Valkov, Tom Donnem, Eivind Smeland, Khalid Al-Shibli, Roy M Bremnes, Lill-Tove Busund.   

Abstract

The immune status is important in cancer patients. Tissue microarrays from 249 patients with soft tissue sarcomas were constructed. Immunohistochemistry was used to evaluate the CD3+, CD4+, CD8+, CD20+ and CD45+ lymphocytes in tumors. High density of CD20+ lymphocytes is an independent positive prognostic indicator for these patients.

Entities:  

Year:  2012        PMID： 22720216      PMCID： PMC3376973          DOI： 10.4161/onci.1.1.17825

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  8 in total

Review 1.  Paradoxical roles of the immune system during cancer development.

Authors:  Karin E de Visser; Alexandra Eichten; Lisa M Coussens
Journal:  Nat Rev Cancer       Date:  2006-01       Impact factor: 60.716

2.  CD4+ T cells in the absence of the CD8+ cytotoxic T cells are critical and sufficient for NKT cell-dependent tumor rejection.

Authors:  Changwan Hong; Hyunji Lee; Mihwa Oh; Chang-Yuil Kang; Seokmann Hong; Se-Ho Park
Journal:  J Immunol       Date:  2006-11-15       Impact factor: 5.422

3.  Tissue microarrays (TMAs) for high-throughput molecular pathology research.

Authors:  A Nocito; J Kononen; O P Kallioniemi; G Sauter
Journal:  Int J Cancer       Date:  2001-10-01       Impact factor: 7.396

4.  Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy.

Authors:  S Mukai; J Kjaergaard; S Shu; G E Plautz
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

5.  NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma.

Authors:  Hiep Phuc Dong; Mari Bunkholt Elstrand; Arild Holth; Ilvars Silins; Aasmund Berner; Claes G Trope; Ben Davidson; Björn Risberg
Journal:  Am J Clin Pathol       Date:  2006-03       Impact factor: 2.493

6.  Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer.

Authors:  Khalid I Al-Shibli; Tom Donnem; Samer Al-Saad; Magnus Persson; Roy M Bremnes; Lill-Tove Busund
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

7.  Prognostic impact of lymphocytes in soft tissue sarcomas.

Authors:  Sveinung W Sorbye; Thomas Kilvaer; Andrej Valkov; Tom Donnem; Eivind Smeland; Khalid Al-Shibli; Roy M Bremnes; Lill-Tove Busund
Journal:  PLoS One       Date:  2011-01-27       Impact factor: 3.240

8.  Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma.

Authors:  Dominik Pretscher; Luitpold V Distel; Gerhard G Grabenbauer; Michael Wittlinger; Maike Buettner; Gerald Niedobitek
Journal:  BMC Cancer       Date:  2009-08-22       Impact factor: 4.430
  8 in total
  11 in total

Review 1.  Trial Watch: Radioimmunotherapy for oncological indications.

Authors:  Norma Bloy; Jonathan Pol; Gwenola Manic; Ilio Vitale; Alexander Eggermont; Jérôme Galon; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-13       Impact factor: 8.110

Review 2.  Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?

Authors:  Joseph M Ryan; Jeffrey S Wasser; Adam J Adler; Anthony T Vella
Journal:  Expert Opin Biol Ther       Date:  2016-02-25       Impact factor: 4.388

3.  Inflammatory Variant of Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma of the Buccal Mucosa: An Overview and Case Report with a 10-Year Follow-Up.

Authors:  José Alcides Almeida de Arruda; Diego Antônio Costa Arantes; Lauren Frenzel Schuch; Lucas Guimarães Abreu; Bruno Augusto Benevenuto de Andrade; Mário José Romañach; Ricardo Alves Mesquita; Satiro Watanabe; José Carlos de Oliveira; Elismauro Francisco Mendonça
Journal:  Head Neck Pathol       Date:  2020-10-22

Review 4.  B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome.

Authors:  Wolf H Fridman; Maxime Meylan; Florent Petitprez; Cheng-Ming Sun; Antoine Italiano; Catherine Sautès-Fridman
Journal:  Nat Rev Clin Oncol       Date:  2022-04-01       Impact factor: 65.011

5.  PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue - prognostic implications and rationale for immunotherapy.

Authors:  Melanie Boxberg; Katja Steiger; Ulrich Lenze; Hans Rechl; Rüdiger von Eisenhart-Rothe; Klaus Wörtler; Wilko Weichert; Rupert Langer; Katja Specht
Journal:  Oncoimmunology       Date:  2017-11-20       Impact factor: 8.110

6.  Clinical evaluation of systemic and local immune responses in cancer: time for integration.

Authors:  Dmitriy W Gutkin; Michael R Shurin
Journal:  Cancer Immunol Immunother       Date:  2013-10-08       Impact factor: 6.968

Review 7.  Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy.

Authors:  Erika Vacchelli; Fernando Aranda; Alexander Eggermont; Jérôme Galon; Catherine Sautès-Fridman; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-01-01       Impact factor: 8.110

8.  Influence of tumor-infiltrating immune cells on local control rate, distant metastasis, and survival in patients with soft tissue sarcoma.

Authors:  Maria A Smolle; Laurin Herbsthofer; Mark Goda; Barbara Granegger; Iva Brcic; Marko Bergovec; Susanne Scheipl; Barbara Prietl; Amin El-Heliebi; Martin Pichler; Armin Gerger; Florian Posch; Martina Tomberger; Pablo López-García; Julia Feichtinger; Claudia Baumgartner; Andreas Leithner; Bernadette Liegl-Atzwanger; Joanna Szkandera
Journal:  Oncoimmunology       Date:  2021-03-11       Impact factor: 8.110

9.  Trial watch: Monoclonal antibodies in cancer therapy.

Authors:  Erika Vacchelli; Alexander Eggermont; Jérôme Galon; Catherine Sautès-Fridman; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-01-01       Impact factor: 8.110

10.  Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy.

Authors:  Fernando Aranda; Erika Vacchelli; Alexander Eggermont; Jerome Galon; Wolf Hervé Fridman; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-02-01       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.